Resumen
Cancer and atrial fibrillation share an enhanced bleeding and thrombotic risk, nevertheless in cancer populations optimal anticoagulation regiments are yet to be validated. This meta-analysis aimed to gather the currently available evidence addressing the use of DOACs in atrial fibrillation cancer patients compared to Warfarin. In the oncological population, DOACs confer benefits in terms of stroke, major and minor bleeding, and thrombotic events, although prospective studies are awaited to strengthen the body of evidence currently available.